Cargando…

The urgent need to recover MHC class I in cancers for effective immunotherapy

Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blockin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garrido, Federico, Aptsiauri, Natalia, Doorduijn, Elien M, Garcia Lora, Angel M, van Hall, Thorbald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138279/ https://www.ncbi.nlm.nih.gov/pubmed/26796069 http://dx.doi.org/10.1016/j.coi.2015.12.007

Ejemplares similares

T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1(b) with TAP-Independent Peptides Are Semi-Invariant Lymphocytes
por: Doorduijn, Elien M., et al.
Publicado: (2018)

Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome
por: Oliveira, Cláudia C., et al.
Publicado: (2015)

MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy
por: Romero, Irene, et al.
Publicado: (2018)

The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture
por: Garrido, Federico, et al.
Publicado: (2017)

Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines
por: Rodríguez, Teresa, et al.
Publicado: (2007)

Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer
por: Garrido, Maria Antonia, et al.
Publicado: (2021)

MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
por: Cornel, Annelisa M., et al.
Publicado: (2020)

Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes
por: Gil-Julio, Hernani, et al.
Publicado: (2021)

MHC class I multimers
por: Sun, Mei-Yi, et al.
Publicado: (2001)

Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I–deficient and MHC I(+) tumors
por: Wolf, Natalie K., et al.
Publicado: (2022)

T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy
por: Doorduijn, Elien M., et al.
Publicado: (2017)

Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine
por: Pulido, María, et al.
Publicado: (2020)

HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
por: Perea, Francisco, et al.
Publicado: (2017)

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
por: Garrido, Greta, et al.
Publicado: (2017)

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
por: Reits, Eric A., et al.
Publicado: (2006)

MHC class I diversity in chimpanzees and bonobos
por: Maibach, Vincent, et al.
Publicado: (2017)

MHC Class I Regulation: The Origin Perspective
por: Sznarkowska, Alicja, et al.
Publicado: (2020)

MHC class I–deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I–sufficient environment
por: Elliott, Julie M., et al.
Publicado: (2010)

Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx.
por: Esteban, F., et al.
Publicado: (1990)

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
por: Taylor, Brandie C., et al.
Publicado: (2022)

The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy
por: Shukla, Akhil, et al.
Publicado: (2021)

Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation
por: Wieczorek, Marek, et al.
Publicado: (2017)

Design of Peptide Immunotherapies for MHC Class-II-Associated Autoimmune Disorders
por: Fridkis-Hareli, Masha
Publicado: (2013)

Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
por: Thibodeau, Jacques, et al.
Publicado: (2012)

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
por: Šímová, J, et al.
Publicado: (2011)

Discovery of an ancient MHC category with both class I and class II features
por: Okamura, Kazuhiko, et al.
Publicado: (2021)

MHC class I evolution; from Northern pike to salmonids
por: Grimholt, U., et al.
Publicado: (2021)

Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection
Publicado: (1987)

Dynamically Driven Allostery in MHC Proteins: Peptide-Dependent Tuning of Class I MHC Global Flexibility
por: Ayres, Cory M., et al.
Publicado: (2019)

The MHC class I peptide repertoire is molded by the transcriptome
por: Fortier, Marie-Hélène, et al.
Publicado: (2008)

MHC class I characterization of Indonesian cynomolgus macaques
por: Pendley, Chad J., et al.
Publicado: (2008)

Predicting MHC class I epitopes in large datasets
por: Roomp, Kirsten, et al.
Publicado: (2010)

Flu DRiPs in MHC Class I Immunosurveillance
por: Wei, Jiajie, et al.
Publicado: (2018)

Involvement of autophagy in MHC class I antigen presentation
por: Øynebråten, Inger
Publicado: (2020)

Mechanistic diversity in MHC class I antigen recognition
por: Barbosa, Camila R. R., et al.
Publicado: (2021)

MHC Class I Immunopeptidome: Past, Present, and Future
por: Yewdell, Jonathan W.
Publicado: (2022)

MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up.
por: Esteban, F., et al.
Publicado: (1996)

Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity
por: Garrido, Greta, et al.
Publicado: (2019)

Differential MHC class I expression in distinct leukocyte subsets
por: Greene, Justin M, et al.
Publicado: (2011)

TAPBPR isoforms exhibit altered association with MHC class I
por: Porter, Keith M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l10rv0ucpck98g6f1elitcnjbk